Stebbing et al. demonstrated that baricitinib, approved as a treatment for adult rheumatoid arthritis, can be a potential therapeutic through the inhibition of viral endocytosis or blockade of JAK1/2 kinase [88]. Here, JAK1 is linked to rheumatoid arthritis.